Results from this trial show the clinical efficacy of direct transition from multiple daily injections to tubeless AID in adults and children with type 1 diabetes, with no safety concerns, supporting AID as a therapeutic option within standard of care for people with type 1 diabetes.
The Lancet Diabetes & Endocrinology published a clinical update in Research Highlights on 23 Feb 2026.
The item focuses on Tubeless automated insulin delivery versus multiple daily injections in children and adults with type 1 diabetes with elevated HbA1c (RADIANT): a multicentre, international, parallel-group, open-label, randomised, controlled trial.
Review the original article for the full source wording and details.